Display options
Cite
Guo W, Zheng Y, Xu B, et al. Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors. Onco Targets Ther. 2017;10:1475-1485doi: 10.2147/OTT.S92389.
Guo, W., Zheng, Y., Xu, B., Ma, F., Li, C., Zhang, X., Wang, Y., & Chang, X. (2017). Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors. OncoTargets and therapy, 101475-1485. https://doi.org/10.2147/OTT.S92389
Guo, Wei, et al. "Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors." OncoTargets and therapy vol. 10 (2017): 1475-1485. doi: https://doi.org/10.2147/OTT.S92389
Guo W, Zheng Y, Xu B, Ma F, Li C, Zhang X, Wang Y, Chang X. Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors. Onco Targets Ther. 2017 Mar 08;10:1475-1485. doi: 10.2147/OTT.S92389. eCollection 2017. PMID: 28331341; PMCID: PMC5352236.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2017 Mar 08;10:1475-1485. doi: 10.2147/OTT.S92389. eCollection 2017.

Investigating the expression, effect and tumorigenic pathway of PADI2 in tumors.

OncoTargets and therapy

Wei Guo, Yabing Zheng, Bing Xu, Fang Ma, Chang Li, Xiaoqian Zhang, Yao Wang, Xiaotian Chang

Affiliations

  1. Medical Research Center, Shandong Provincial Qianfoshan Hospital; Obstetrical Department, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong.
  2. Obstetrical Department, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, Shandong.
  3. Medical Research Center, Shandong Provincial Qianfoshan Hospital.
  4. Pathology Department, Tengzhou Central People's Hospital, Tengzhou.
  5. Clinical Laboratory, PKU Care Luzhong Hospital, Zibo, Shandong, People's Republic of China.

PMID: 28331341 PMCID: PMC5352236 DOI: 10.2147/OTT.S92389

Abstract

BACKGROUND: Peptidylarginine deiminase (PAD) catalyzes the conversion of arginine residues to citrulline residues, termed citrullination. Recent studies have suggested that PAD isoform 2 (PADI2) plays an important role in tumors, although its tumorigenic effect and mechanism are largely unknown.

MATERIALS AND METHODS: Immunohistochemistry and enzyme-linked immunosorbent assay (ELISA) were used to investigate the expression level of PADI2 in various tumor tissues and patient blood samples, respectively. MNK-45 and Bel-7402 tumor cell lines originating from gastric and liver tumors, respectively, were treated with anti-PADI2 siRNA, and the subsequent cell proliferation, apoptosis and migration were observed. Polymerase chain reaction (PCR) arrays, including Cancer PathwayFinder, Oncogenes and Tumor Suppressor Genes, p53 Signaling Pathway, Signal Transduction Pathway and Tumor Metastasis PCR arrays, were used to investigate the tumorigenic pathway of PADI2 in the siRNA-treated tumor cells. This analysis was verified by real-time PCR.

RESULTS: Immunohistochemistry detected significantly increased expression of PADI2 in invasive breast ductal carcinoma, cervical squamous cell carcinoma, colon adenocarcinoma, liver hepatocellular carcinoma, lung cancer, ovarian serous papillary adenocarcinoma and papillary thyroid carcinoma samples. ELISA detected a twofold increase in PADI2 expression in the blood of 48.3% of patients with liver cancer, 38% of patients with cervical carcinoma and 32% of patients with gastric carcinoma. Increased apoptosis and decreased cell proliferation and migration were observed in the anti-PADI2 siRNA-treated MNK-45 cells, and increased cell proliferation and migration and decreased apoptosis were observed in the treated Bel-7402 cells with suppressed PADI2 expression. PCR arrays and real-time PCR detected significantly decreased CXCR2 and EPO expression in the MNK-45 cells and Bel-7402 cells, respectively, with the anti-PADI2 siRNA treatments.

CONCLUSION: PADI2 expression is increased in many types of tumor tissues and patient blood samples. PADI2 may advance abnormal cell behavior in gastric cancers by mediating CXCR2, a well-known gene that stimulates cell proliferation and invasion. However, PADI2 might have deleterious effects on tumor growth and metastasis in liver tumor cells by regulating the expression of EPO, a gene with controversial functions in tumor growth. The results suggest that the effect of PADI2 on tumorigenesis is multifactorial, depending on the tumor type.

Keywords: CXCR2; EPO; PADI2; pathway; tumorigenesis

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

References

  1. ISRN Oncol. 2013 Oct 09;2013:859154 - PubMed
  2. J Transl Med. 2009 Apr 14;7:25 - PubMed
  3. Oncotarget. 2016 Sep 20;7(38):62159-62176 - PubMed
  4. Pathobiology. 2011;78(1):41-53 - PubMed
  5. Int J Clin Exp Pathol. 2015 Apr 01;8(4):4033-43 - PubMed
  6. Lancet Oncol. 2016 Aug;17(8):e325 - PubMed
  7. Avian Dis. 1984 Jan-Mar;28(1):208-15 - PubMed
  8. Biochem Res Int. 2012;2012:895343 - PubMed
  9. Cytokine Growth Factor Rev. 2016 Oct;31:61-71 - PubMed
  10. Cancer Cell Int. 2016 Jul 29;16:61 - PubMed
  11. Mol Cancer Res. 2016 Sep;14(9):841-8 - PubMed
  12. Neurosci Lett. 1999 May 14;266(3):161-4 - PubMed
  13. J Dermatol Sci. 2006 Nov;44(2):63-72 - PubMed
  14. Cancer Lett. 2013 Sep 1;337(2):276-84 - PubMed
  15. Nat Struct Mol Biol. 2004 Aug;11(8):777-83 - PubMed
  16. Cancer Res. 2014 Nov 1;74(21):6306-17 - PubMed
  17. Amyloid. 2015;22(2):93-9 - PubMed
  18. Ann Oncol. 2011 Oct;22(10):2267-76 - PubMed
  19. Int J Oncol. 2016 Apr;48(4):1341-52 - PubMed
  20. Arch Toxicol. 2014 Jan;88(1):89-96 - PubMed
  21. Oncologist. 2004;9 Suppl 5:18-30 - PubMed
  22. BMC Cancer. 2012 Oct 30;12:500 - PubMed
  23. Curr Opin Chem Biol. 2016 Aug;33:169-78 - PubMed
  24. Cell Mol Life Sci. 2010 May;67(9):1491-503 - PubMed

Publication Types